-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22

Benzinga·06/29/2026 13:56:12
Listen to the news
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $21 to $22.